every opportunity to change lives and ultimately … opportunity to change lives and ultimately defeat cancer. ... Zeshaan Rasheed, M.D., ... Nike, Inc. Michael W. Krzyzewski

2013 Annual Report1

“I know where I am, and I know where I’m going and I know I’m going to get there. I’m going to be excited and enthusiastic every day that God gives me on this earth. I am going to dream my dreams.”

– j i m va lva n o

2013 Annual Report1

CEO Message

2

The V Foundation for Cancer Research is a charitable organization

dedicated to saving lives by helping to find cures for cancer. The V

Foundation strives to make a difference by generating extensive,

passionate support for cancer research and by creating an urgent

awareness among all Americans of the importance of ending the

disease in all its forms. The dedicated work of our many partners,

volunteers and supporters has led to many extraordinary, tangible

victories in the war against cancer. Through advocacy, education,

fundraising, and philanthropy, The V Foundation continues to seize

every opportunity to change lives and ultimately defeat cancer.

The V Foundation has spent 21 years funding research that brings

together the brightest minds working to end cancer. We are proud

to present our annual report, providing a snapshot of last year’s

accomplishments. During fiscal year 2013, we funded $14 million in

new cancer research grants, and continue to fund previous multi-

year grants. We are making important progress! This report is also a

prelude to the future – a look at how to expedite this fight, to make

it as effective as possible, to enlist each of you in this effort so that

we can end cancer. Thank you for your help and support. No one

can change the course of cancer alone. We dedicate this report to

everyone working together toward this goal. Please help us continue

until there is no longer a need.

Susan BraunChief Executive Officer

Our Mission

2013 Annual Report

2013 Annual Report3

The V Foundation awards three types of grants. The V Scholar

grant directly funds young investigators to help them establish

their own independent laboratory research projects. The

Translational grant facilitates the transition of projects from the

laboratory to the patient’s beside quickly and efficiently. The

Designated grants are inspired by particular areas of scientific

interest and/or geographic reach. They are selected on the basis

of scientific merit, as determined by our scientific advisors.

v S c h o l a r S

Bjoern Schwer, M.D., Ph.D.Boston Children’s HospitalBoston, MAMartin D. Abeloff, M.D. V ScholarNeural Genome Rearrangements and Alternative end Joining Processes in Initiation and Maintenance of Medulloblstoma

Maximilian Diehn, M.D., Ph.D.Stanford Cancer InstituteStanford, CAInvestigating the KEAP1-NRF2 Pathway in Lung Stem Cells and Lung CancerAlbert Wyrick V Scholar AwardFunded by The Michael and Carole Marks Family

Rafael Bejar, M.D., Ph.D.UCSD Moores Cancer CenterLa Jolla, CA Pathogenic Mechanisms of Splicing Factor Mutations in Myelodysplastic Syndromes

Timothy F. Burns, M.D., Ph.D.University of Pittsburgh Cancer InstitutePittsburgh, PATargeting KRAS Mutant Lung Adenocarcinoma through Inhibition of TWIST 1Supported by UNICO National in Memory of Sue Speciale

Luis Carvajal-Carmona, Ph.D.University of California, DavisSacramento, CA Identification of Novel Breast Cancer Genes in a Hispanic Isolate

Robert Doebele, M.D., Ph.D.University of Colorado School of MedicineDepartment of Medicine, Division of Medical OncologyAurora, CO NTRK1 Gene Fusions as a Novel Oncogene Class and Therapeutic Target in Lung Cancer Funded in Memory of Calvin Bradham with support from Crown Imports

Michael J. Emanuele, Ph.D.Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel HillChapel Hill, NCIdentification of Ubiquitin Signaling Networks as Novel Avenues for Therapeutic Intervention

Summer Gibbs, Ph.D.Oregon Health & Science UniversityPortland, ORScreening of Small Molecule Fluorophores to Probe Pancreatic Cancer Margins in the Operating Room

2013 Grants

2013 Annual Report 4

Peter Hammerman, M.D., Ph.D.Dana-Farber Cancer InstituteBoston, MATargeting Fibroblast Growth Factor Receptor Fusions in Lung and Head and Neck Cancer

Mei Kong, Ph.D.Beckman Research Institute of the City of HopeDuarte, CATargeting Glutamine Metabolism and the B55a-p53 Survival Pathway for Lymphoma Treatment

Christopher A. Maher, Ph.D.Siteman Cancer CenterWashington UniversitySt. Louis, MOUnderstanding the Role of Polycomb Associated LncRNAs in Prostate Cancer2013 Vintner Grant – Funded by The Wine CelebrationIn Honor of Fred and Mary Constant, Jeff and Valerie Gargiulo, Dick and Ann Grace, Fred and Sally Schweiger, and Lowell and Janet Herrero

Michael Kharas, Ph.D.Memorial Sloan-Kettering Cancer CenterNew York, NYUnderstanding the MSI2 RNA Binding Protein Network in Leukemia

George-Lucian Moldovan, Ph.D.Penn State Hershey Cancer InstituteHershey, PA Dysregulation of the PARI Genomic Stability Pathway in Leukemia

Zeshaan Rasheed, M.D., Ph.D.The Sidney Kimmel Comprehensive Cancer CenterBaltimore, MDRegulatory Effects of the Tumor Microenvironment on Stem Cell Plasticity in Pancreatic Ductal Adenocarcinoma

Jatin Roper, M.D.Tufts Medical CenterBoston, MAThe Role of IWS1 and FGFR2 Isoform IIIc in Akt Isoform-dependent Colorectal Carcinogenesis

Ryan A. Wilcox, M.D., Ph.D.University of Michigan Comprehensive Cancer CenterAnn Arbor, MIRole of the T-cell Transcription Factor GATA-3 in Cutaneous T-cell Lymphomas

Kris C. Wood, Ph.D.Duke Cancer InstituteDurham, NCSystematic Identification of Combination Therapies Targeting the Breast Cancer Microenvironment2013 V Foundation Wine Celebration Vounteer Grant in Honor of John and Anne Sachs

Chunling Yi, Ph.D.Lombardi Comprehensive Cancer CenterGeorgetown UniversityWashington, DCInterrogating the Role of Hippo-Yap Growth Regulatory Pathway in Kidney Cancer

2013 Annual Report5

2 0 1 3 T r a n S l aT i o n a l G r a n T S

Nika Danial, Ph.D.Margaret Shipp, M.D.Jarrod Marto, Ph.D.Dana-Farber Cancer InstituteBoston, MAFueling DLBCL Proliferation and Survival: A Role for Fatty Acid Metabolism

Ralph Deberardinis, M.D., Ph.D.Kemp Kernstein, M.D., Ph.D.Children’s Medical Center Research Institute at Universtiy of Texas SouthwesternDallas, TXFunded in Memory of Christopher T. CarrollTranslational Studies in Lung Cancer Metabolism: Creating New Paradigms in Diagnosis and Therapy

Gianpietro Dotti, M.D.Cliona Rooney, Ph.D.Caridad Martinez, M.D.Dan L. Duncan Cancer Center at Baylor College of MedicineHouston, TXPrevention and Treatment of Viral Infections and Leukemic Relapse after Allogeneic Stem Cell Transplantation

Benjamin L. Ebert, M.D., Ph.D.Ann Mullally, M.D.William Kaelin, Jr., M.D.David Steensma, M.D.Brigham and Women’s HospitalBoston, MAIdentifying and Targeting Oncogenic Pathways in TET2 and IDH Mutant Myeloid Malignancies

Tanja A. Gruber, M.D., Ph.D.James R. Downing, M.D.St. Jude Children’s Research HospitalMemphis, TNFunded by the 2013 Dick Vitale Gala In Honor of Dick and Lorraine VitaleIdentification of Active Compounds in Infantile Acute Lymphoblastic Leukemia

John V. Heymach, M.D., Ph.D.Varsha Gandhi, Ph.D.Christine Stellrecht, Ph.D.Carlo Toniatti, M.D., Ph.D.Timothy Heffernan, Ph.D.The University of Texas MD Anderson Cancer CenterHouston, TXAttacking the Specific Vulnerability of LKB1-Mutant NSCLC to Energy Depletion Using an ATP Mimetic

Ite A.Laird-Offringa, Ph.D.Barbara Gitlitz, M.D.Martin W. Kast, Ph.D.Kimberly Siegmund, Ph.D.Lina Wang, M.D.Michael Wong, M.D., Ph.D.USC Norris Comprehensive Cancer CenterLos Angeles, CADevelopment of Immunotherapy for Small Cell Lung Cancer using Novel Modified Antigens

Daniela Matei, M.D.Kenneth P. Nephew, Ph.D.Indiana University Melvin and Bren Simon Cancer CenterIndianapolis, INAn Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer

Toshi Tanuiguchi, M.D., Ph.D.Elizabeth M. Swisher, M.D.Fred Hutchinson Cancer CenterSeattle, WADefining Genomic Scarring and Functional DNA Variants that Predict Response to PARP Inhibitors in a Clinical Trial for Recurrent Ovarian Cancer

Pengbo Zhou, Ph.D.Leonard Salta, M.D.Yao-Tseng Chen, M.D., Ph.D.Weill Cornell Medical CollegeNew York, NYUbiquitin Ligase as a Novel Diagnostic Marker and Therapeutic Target for Colorectal CancerFunded by The V Foundation Wine CelebrationIn Honor of Steve Bornstein

2013 Grants


2 0 1 3 D e S i G n aT e D G r a n T S

Lizi Wu, Ph.D.Shands Cancer CenterUniversity of FloridaGainesville, FLRegulation of Oncogenic NOTCH Signaling in Childhood LeukemiaFunded by 2012 Dick Vitale GalaIn Memory of Caleb Gacobbe

Daniel S. Wechsler, M.D., Ph.D.Duke University Medical CenterDurham, NCTherapeutic Targeting of Calm-AF10 Nuclear Export in Pediatric LeukemiaFunded by The Apple Gold Group

Stuart Goldberg, M.D.Hackensack University Medical CenterThe John Theurer Cancer CenterHackensack, NJThe Use of Dynamic Single Cell Network Profile to Predict Outcome in Newly Diagnosed Acute Myelogenous Leukemia (AML)Funded by Marketing Research ConsultantsIn Memory of Mary Ann Ingoglia

Victoria Belancio, Ph.D.Tulane UniversityTulane Cancer CenterNew Orleans, LALine-1 Contributing to Lung Cancer in VivoFunded by The Kay Yow Cancer Fund

Shari Pilon-Thomas, Ph.D.William E. Janssen, M.D.H. Lee Moffitt Cancer Center & Research InstituteTampa, FLAdoptive Cell Therapy for NeuroblastomaFunded by 2012 Dick Vitale GalaIn memory of Dave Heard

Queen of the Valley Medical CenterNapa, CAFunded by The V Foundation Wine CelebrationClinical Laboratory and Pathology ServicesHerman Family Advanced Diagnostic and Surgical Services Pavilion

Amit K. Verma, M.D.David J. Prezant, M.D.Mayris Webber, M.P.H., Dr. P.H.Charles B. Hall, Ph.D.Albert Einstein College of Medicine of Yeshiva Universi-tyBronx, NYEarly Detection of Hematologic Malignancies in New York City Firefighters Exposed to World Trade Center Dust after the 9/11 AttacksFunded by The V Foundation Wine Celebration and Jimmy V Celebrity Golf Classic

St. Helena HospitalNapa, CAClinical Research Program at St. Helena Hospital Martin-O’Neil Cancer CenterFunded by The V Foundation Wine Celebration

Calvin Lee, M.D.All Children’s HospitalSt. Petersburg, FLBMI1’s Role in the Regulation of Myogenic Differentiation in RhabdomyosarcomaFunded by 2013 Dick Vitale Gala

John Cavanagh, Ph.D.North Carolina State Jimmy V Cancer Therapeutics ProgramRaleigh, NC Funded by 2013 Jimmy V Celebrity Golf ClassicIn Honor of the JVCGC 20 Year Volunteers

James M. Ford, M.D.Stanford University School of MedicineStanford, CA Funded by The Gastric Cancer FoundationGastric Cancer Genomic Research

Daniel S. Wechsler, M.D., Ph.D.Catherine P. Lavau, DVM, Ph.D.Duke University Medical CenterDurham, NCA Novel Role for the CRM1 Nuclear Export Receptor in Leukemogenesis: Mechanisms and TargetingFunded by The Apple Gold Group

2013 Annual Report7

Jim AllegroEmeritus DirectorThe V Foundation for Cancer Research

Julie AllegroGeneral PartnerAllegro Venture Partners

Robert C. Bast, Jr., M.D.Vice President for Translational ResearchThe University of Texas MD Anderson Cancer Center

George BodenheimerExecutive ChairmanESPN, Inc.

Steven M. BornsteinFormer President and Chief Executive Officer NFL NetworkBoard ChairThe V Foundation for Cancer Research

Bill Cosby

George W. Dennis IIIRetired Senior PartnerTeague Campbell Dennis & Gorham, LLP

David B. FayRetired Executive DirectorUnited States Golf Association

Rosa M. GattiRetired Senior Vice President, Communications Counsel and Corporate OutreachESPN, Inc.

Mark KingPresidentAdidas Group North America

Philip H. KnightChairman of the BoardNike, Inc.

Michael W. KrzyzewskiHead Coach, Men’s BasketballDuke University

Eric LautenbachDirector of College Basketball Sports MarketingNike, Inc.

Carl C. Liebert IIIPresident USAA Capital Corporation

Robert E. LloydChair EmeritusThe V Foundation for Cancer Research

Joe LoughreyRetired President and Vice ChairmanCummins, Inc.

Michael C. Mac DonaldChairman and Chief Executive OfficerMedifast

Board of Directors

The V Foundation Board of Directors is entrusted with and

accountable for the strategic leadership and governance of the

organization. Comprised of prominent business leaders, award-

winning athletes and coaches, distinguished physicians and

world-renowned entertainers, the Board provides governance and

insight into sustaining and continually improving the Foundation’s

efforts in the fight against cancer.


Michael E. MarksFounding PartnerRiverwood Capital, LLC

Geoffrey S. Mason Senior Production SpecialistESPN, Inc.

Joseph O. Moore, M.D.Professor of MedicineDuke Cancer Institute

Robert C. NakasoneRetired Chief Executive OfficerToys “R” Us, Inc.

Donna OrenderChief Executive OfficerOrender Unlimited, LLC

Lawrence F. Probst IIIChairman of the BoardElectronic Arts

Harry E. Rhoads, Jr.Chief Executive OfficerWashington Speakers Bureau

Robin RobertsCo-AnchorABC’s Good Morning America

John P. SaundersSports CommentatorESPN, Inc. and ABC Sports

Constance SkidmoreRetired Board Member – Managing Partner PricewaterhouseCoopers LLP

John SkipperCo-ChairDisney Media NetworksPresidentESPN, Inc.

Tony F. Smith, Ph.D.Managing DirectorLeadership Research Institute

Pamela Valvano StrasserChairwomanThe V Foundation for Cancer Research

Stuart TaylorChief Executive Officer The Taylor Group

Nicholas P. ValvanoPresident Emeritus The V Foundation for Cancer Research

Robert ValvanoSports Commentator

Lesley VisserSports CommentatorCBS and HBO

Dick VitaleSports CommentatorESPN, Inc. and ABC Sports

R.C. “Bucky” WatersRetired Vice ChancellorDuke University Medical Center

Robert P. WaymanRetired Chief Financial Officer and Executive Vice President Hewlett-Packard Company

Dereck WhittenburgDirector of Player DevelopmentNorth Carolina State University

David W. WilliamsRetired Senior Vice PresidentWhirlpool Corporation

Norby WilliamsonExecutive Vice President, Programming & AcquisitionsESPN, Inc.

Larry WoodardPresident and Chief Executive OfficerGraham Stanley Advertising

Susan BraunEx OfficioChief Executive Officer The V Foundation for Cancer Research

2013 Annual Report9

Scientific Advisory Committee

The Scientific Advisory Committee is composed of leading

physicians and research scientists from prominent universities

and cancer centers. The all-volunteer Committee reviews and

recommends top-rated research projects from the brightest

innovators exploring the mysteries of cancer. Their guidance

safeguards the scientific merit of grant proposals and ultimately

provides funding to the leading pioneers in the field of

cancer research.

Martin D. Abeloff, M.D. (In Memoriam) Sidney Kimmel Comprehensive Cancer Center

Robert C. Bast, Jr., M.D.The University of Texas MD Anderson Cancer Center

William T. Beck, Ph.D.University of Illinois at Chicago

Lisa Coussens, Ph. D. Oregon Health & Science University

Nancy Davidson, M.D. University of Pittsburgh Cancer Institute

H. Shelton Earp III, M.D.UNC Lineberger Comprehensive Cancer Center

Paul F. Engstrom, M.D.Fox Chase Cancer Center

Olivera J. Finn, Ph.D.University of Pittsburgh School of Medicine

Richard I. Fisher, M.D.Fox Chase Cancer Center

James M. Ford, M.D.Stanford University School of Medicine


Susan Hilsenbeck, Ph.D.Baylor College of Medicine

Theodore S. Lawrence, M.D., Ph.D.University of Michigan Comprehensive Cancer Center

A. Thomas Look, M.D. Dana-Farber Cancer Institute

John D. Minna, M.D. University of Texas Southwestern Medical Center

Joseph O. Moore, M.D.Duke Cancer Institute

William G. Nelson, M.D., Ph.D.Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brian Patrick O’Neill, M.D. Mayo Clinic Cancer Center

Richard O’Reilly, M.D.Memorial Sloan-Kettering Cancer Center

David Piwinica-Worms, M.D., Ph.D. The University of Texas MD Anderson Cancer Center

Helen Piwinica-Worms, Ph.D. The University of Texas MD Anderson Cancer Center

Jerome Ritz, M.D.Dana-Farber Cancer Institute

David E. Schuller, M.D.The Ohio State University Comprehensive Cancer Center

Jonathan W. Simons, M.D.Prostate Cancer Foundation

Margaret A. Tempero, M.D.UCSF Comprehensive Cancer Center

2013 Annual Report11

c U r r e n T a S S e T S :

Cash and cash equivalentsAccounts receivable, netPromises to give, net Prepaid expenses

T o Ta l c U r r e n T a S S e T S

Property and Equipment, Net

o T h e r a S S e T S :Investments Promises to give, netIntangible assets

T o Ta l o T h e r a S S e T S

T o Ta l a S S e T S

Statement of Financial Position

September 30, 2013

Assets

2 0 1 3

$ 11,730,389213,495

2,136,430151,737

14,232,051

48,515

22,446,4543,413,097

50,000

25,909,551

$40,190,117


c U r r e n T l i a B i l i T i e S :

Accounts payable and accrued expenses Accrued payroll and related liabilitiesDeferred rent Grants payable

T o Ta l c U r r e n T l i a B i l i T i e S

lo n G -T e r ml i a B i l i T i e S :Grants payable, net

T o Ta l l i a B i l i T i e S

n e T a S S e T S :Unrestricted: Board designatedUndesignated

Temporarily restrictedPermanently restricted

T o Ta l n e Ta S S e T S

T o Ta l l i a B i l i T i e Sa n D n e T a S S e T S

2 0 1 3

$ 55,18853,96840,350

12,223,413

12,372,919

9,840,300

22,213,219

5,517,136(3,589,825)

1,927,3113,932,57612,117,011

17,976,898

$40,190,117

Liabilities & Net Assets


S U P P o r T a n D r e v e n U e :

Contributions and giftsSpecial events:Contributions Event incomeLess: costs of direct benefits to donorsNet revenues from special events

License incomeInvestment income, net of feesUnrealized gain on investmentsRealized gain on investments

Net assets released from restrictions

T o Ta l S U P P o r T a n D r e v e n U e

e X P e n S e S :Program ServicesSupporting Services:Management and generalFundraising expensesTotal Supporting Services

T o Ta l e X P e n S e S

c h a n G e S i n n e T a S S e T S

T r a n S f e r o f n e T a S S e T S

n e T a S S e T S – B e G i n n i n G o f n e w y e a r

n e T a S S e T S – e n D o f y e a r

U n r e S T r i c T e D $ 10,608,057

1,592,397204,611

(674,660)1,122,348

3,332117,605213,597130,773

12,195,7126,082,391

18,278,103

15,138,098

719,4901,071,164

1,790,654

16,928,752

1,349,351

3,785,000

(3,207,040)

$1,927,311

For the year ended September 30, 2013

Statement of Activities and Changes in Net Assets


T e m P o r a r i lyr e S T r i c T e D

$ 5,085,610

–––––

266,906513,399314,326

6,180,241(6,082,391)

97,850

–

–––

–

P e r m a n e n T lyr e S T r i c T e D

$ 145,899

––––––––

145,889–

145,889

–

–––

–

2 0 1 3T o Ta l S

$ 15,839,566

1,592,397204,611

(674,660)1,122,348

3,332384,511

726,996445,099

18,521,852–

18,521,852

15,138,098

719,4901,071,164

1,790,654

16,928,752

1,593,100

–

16,383,798

$17,976,898

97,850

–

3,834,726

$3,932,576

145,899

(3,785,000)

15,756,112

$12,117,011


CA

MN

IL INOH

PA NJ

MD

MA

VA

NCTN

TX

FL

NY

AL

AZ

CO

CT

DC

GA

HI

IA

ID

KY

LA

ME

MI

MO

NE

NM

OR

SC

UT

WA

WI

WV

1994-2013

Grant Distribution by State

NHVT


Grant Distributions by Cancer Site

Leukemia/Lymphoma ($22.1)

General Cancer/Other ($23.5)

Pediatric ($14.1)

Breast ($10.9)

GI ($4.0)

Lung ($11.6)

Melanoma ($6.3)

Prostate ($4.6)

Pancreatic ($5.5)

Gyn./Cervical/Ovarian ($3.1)

Brain ($3.3)

Head and Neck ($1.4)

Renal ($2.9)

Colon ($1.2)

Myeloma ($0.5)

Ewings ($0.8)

$115,436,0545 3 9 T o Ta l G r a n T S

1 9 9 4 - 2 0 1 3 ( i n m i l l i o n S )


Thank You

Thank You for Your Passion, Friendship and Commitment!

People from all walks of life support The V Foundation for Cancer Research.

Your donations are making an impact, advancing life-saving research and providing hope to cancer patients and their loved ones.

Thank you for caring and for all the good things you do to support our cause.

Together, we will win the fight against cancer.

2013 Annual Report1 2013 Annual Report 18

h o P e

Begins in the dark.The road is long.The hills are steep.

Only your support drives us forward.

Documents

every opportunity to change lives and ultimately … opportunity to change lives and ultimately defeat cancer. ... Zeshaan Rasheed, M.D., ... Nike, Inc. Michael W. Krzyzewski